Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mona Gupta

Psychiatry Raleigh, NC Doctor of Osteopathy

NPI 1902923691 CMS profile 759485

8304 Creedmoor Rd, Raleigh, NC 27613

Open in the dashboard

General payments

$88,223

799 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mona Gupta of Raleigh, NC is reported in the CMS Open Payments database as having received $88,223 across 799 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,424 59
2024 General $2,898 32
2023 General $9,471 57
2022 General $18,745 143
2021 General $22,270 168
2020 General $8,143 151
2019 General $25,272 189

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mona Gupta
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Mona Gupta were reported at $1,424. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Mona Gupta Psychiatry median Middle half National median
2019 $25,272 $184 $59–$605 $163
2020 $8,143 $119 $36–$372 $114
2021 $22,270 $143 $43–$576 $132
2022 $18,745 $153 $50–$590 $149
2023 $9,471 $170 $56–$651 $160
2024 $2,898 $179 $57–$673 $164
2025 $1,424 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $22,555 69 payments
  2. Allergan Inc. $16,278 106 payments
  3. Alkermes, Inc. $13,762 57 payments
  4. AbbVie, Inc. $9,629 115 payments
  5. ITI, Inc. $7,727 43 payments
  6. Axsome Therapeutics, Inc. $6,504 10 payments
  7. Sunovion Pharmaceuticals Inc. $4,243 57 payments
  8. Janssen Pharmaceuticals, Inc $2,135 80 payments
  9. Neuronetics, Inc. $792 5 payments
  10. Lundbeck LLC $593 39 payments
  11. Other $4,008 218 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $66,845 53 payments
  2. Food and Beverage $13,456 734 payments
  3. Consulting Fee $3,000 2 payments
  4. Travel and Lodging $2,823 7 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $2,000 1 payment
  6. Education $100 2 payments
Products named General payments · program years 2019–2025
  1. REXULTI $22,385 58 payments
  2. VRAYLAR Neuroscience $15,556 119 payments
  3. LYBALVI Cns $13,151 28 payments
  4. LYBALVI Cns $13,046 23 payments
  5. LYBALVI Cns $12,887 13 payments
  6. LYBALVI Cns $12,887 13 payments
  7. VRAYLAR Neuroscience $10,313 99 payments
  8. CAPLYTA $7,535 38 payments
  9. Auvelity $6,504 10 payments
  10. LATUDA $4,243 57 payments
  11. Other $11,396 524 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

35

Median for Psychiatry & Neurology: 100

Drug cost

$431

Median for Psychiatry & Neurology: $2,986

Branded share of claims

0%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trazodone Hcl Generic 19 $372
Alprazolam Generic 16 $60

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $2,000
$2,000 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $308
$308 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $146
  • Lundbeck LLC $18
$164 — —
VIVITROL
  • Alkermes, Inc. $81
$81 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

799 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record